Endpoints NewsOriginal article
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial
AdComGrail cancer testNegative
AI Analysis
Summary
The FDA will hold an advisory committee meeting in September to review Grail's early cancer detection test following its failure to meet the primary endpoint in a large randomized trial conducted in the UK.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Test failed to meet primary endpoint in large randomized UK trial
Importance:7/10
Sentiment:
-0.70
cancer screeningearly detectionFDA advisory committeeclinical trial failure
Read the original article
Published by Endpoints News on August 7, 2026 4:08 PM